RVPH

Reviva Pharmaceuticals Holdings Inc.

RVPH, USA

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

https://www.revivapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RVPH
stock
RVPH

683 Capital Management LLC Makes New Investment in Reviva Pharmaceuticals Holdings, Inc. $RVPH Defense World

Read more →
RVPH
stock
RVPH

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025 ts2.tech

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$5

Analyst Picks

Strong Buy

3

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

14.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-88.15 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.98 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.15

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 23.90% of the total shares of Reviva Pharmaceuticals Holdings Inc.

1.

Diadema Partners LP

(4.0225%)

since

2025/06/30

2.

Armistice Capital, LLC

(3.9586%)

since

2025/06/30

3.

Heights Capital Management Inc

(2.6909%)

since

2025/06/30

4.

Vanguard Group Inc

(2.6529%)

since

2025/06/30

5.

Millennium Management LLC

(2.1882%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(1.7531%)

since

2025/07/31

7.

683 Capital Management LLC

(1.4705%)

since

2025/06/30

8.

Persistent Asset Partners Limited

(0.9429%)

since

2025/06/30

9.

Geode Capital Management, LLC

(0.6591%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5792%)

since

2025/07/31

11.

SIMPLEX TRADING, LLC

(0.3354%)

since

2025/06/30

12.

Fidelity Extended Market Index

(0.3295%)

since

2025/07/31

13.

Sabby Management LLC

(0.2499%)

since

2025/06/30

14.

Avidity Partners Management LP

(0.2029%)

since

2025/06/30

15.

EMC Capital Management(TX)

(0.1888%)

since

2025/06/30

16.

Schonfeld Strategic Advisors LLC

(0.1871%)

since

2025/06/30

17.

State Street Corp

(0.1863%)

since

2025/06/30

18.

Susquehanna International Group, LLP

(0.1425%)

since

2025/06/30

19.

XTX Topco Ltd

(0.1205%)

since

2025/06/30

20.

Northern Trust Corp

(0.105%)

since

2025/06/30

21.

Fidelity Total Market Index

(0.1008%)

since

2025/07/31

22.

Fidelity Series Total Market Index

(0.0878%)

since

2025/07/31

23.

BlackRock Inc

(0.0846%)

since

2025/06/30

24.

H D Vest Advisory Services

(0.0846%)

since

2025/06/30

25.

The Colony Group LLC

(0.0779%)

since

2025/06/30

26.

Spartan Extended Market Index Pool F

(0.0722%)

since

2025/07/31

27.

Northern Trust Extended Eq Market Idx

(0.0719%)

since

2025/06/30

28.

NT Ext Equity Mkt Idx Fd - L

(0.0719%)

since

2025/06/30

29.

Extended Equity Market Fund K

(0.0686%)

since

2025/06/30

30.

Spartan Total Market Index Pool G

(0.0391%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - NL

(0.0326%)

since

2025/06/30

32.

Fidelity Nasdaq Composite Index

(0.0293%)

since

2025/07/31

33.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0253%)

since

2025/06/30

34.

Schwab Total Stock Market Index

(0.0221%)

since

2025/07/31

35.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0203%)

since

2025/06/30

36.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.012%)

since

2024/12/31

37.

Vanguard U.S. Eq Idx £ Acc

(0.0101%)

since

2025/07/31

38.

Extended Equity Market Fund M

(0.0086%)

since

2025/06/30

39.

State St US Ttl Mkt Indx NL Cl A

(0.0076%)

since

2025/08/31

40.

State St US Extended Mkt Indx NL Cl C

(0.0074%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.06

EPS Estimate

-0.108

EPS Difference

0.048

Surprise Percent

44.4444%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.